Diabetes is associated with a higher risk of dementia, but the evidence does not show that diabetes inevitably causes it. The strongest summary found a 59% higher relative risk, while major differences among studies limit what that number predicts for one person. Dementia describes a decline in memory and thinking that interferes with daily life. For people with diabetes, the practical message is to manage several connected risks—not to expect certainty or rely on a particular drug for prevention.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How large is the association?
- Does diabetes type matter?
- Why do glucose levels and vascular health matter?
- Can a diabetes medicine prevent dementia?
- What can a person do now?
How large is the association?
A 2024 meta-analysis combined 15 studies involving 10.1 million people. It found that diabetes was associated with a 59% higher dementia risk, expressed as a relative risk of 1.59, according to Diabetology & Metabolic Syndrome. Relative risk is easy to misread. A 59% increase does not mean that 59% of people with diabetes will develop dementia. In a hypothetical group with a 10% starting risk, a 59% relative increase would raise that figure to about 16%, not 69%.
The analysis also reported very high variation between studies, with an I² value of 96.4%. In practical terms, the studies did not produce uniform estimates. Differences among populations and methods make the pooled figure unsuitable as a personal forecast. Most importantly, an association does not prove that diabetes alone causes dementia. Age, blood pressure, cardiovascular disease, stroke history, glucose control, and diabetes duration may contribute to the risk seen in research.
Does diabetes type matter?
The evidence suggests that dementia risk is relevant to both major forms of diabetes, although the available findings are not interchangeable. Type 1 diabetes and type 2 diabetes involve different populations, treatment patterns, and risk profiles. In a Swedish nationwide cohort, people with type 1 diabetes had about twice the recorded risk of all-cause dementia compared with matched controls. Researchers also found higher vascular dementia risk and a smaller increase in Alzheimer disease risk, according to the 2025 Diabetes Care study.
Within that type 1 group, risk also varied. Beyond age, higher systolic blood pressure, higher HbA1c, previous stroke or cardiovascular disease, and longer diabetes duration were associated with dementia risk. HbA1c is a measure of average blood glucose over the preceding months. For type 2 diabetes, a 2025 review focused on hypoglycaemia rather than producing one overall diabetes-versus-no-diabetes estimate. That distinction matters: a finding about low-glucose episodes should not be treated as a complete measure of dementia risk for everyone with type 2 diabetes.
Why do glucose levels and vascular health matter?
The CDC states that persistently high and low blood glucose can damage blood vessels in the brain. Long-term high glucose may impair memory and thinking and contribute to vascular dementia, which is linked to problems with blood flow in the brain. Low glucose also deserves attention. A systematic review of 40 longitudinal studies in people with type 2 diabetes associated hypoglycaemia with a 49% higher risk of all-cause dementia and a 31% higher risk of Alzheimer disease, as reported in Diabetic Medicine.
These findings do not show that every low reading causes permanent harm. They do show why treatment should balance the risks of sustained high glucose and repeated or serious lows. Pursuing ever-lower readings without considering hypoglycaemia is not a sound dementia-prevention strategy. Blood pressure and cardiovascular history also matter because diabetes does not operate in isolation. The type 1 cohort's findings point toward a combined risk pattern involving glucose exposure, vascular health, and time lived with diabetes.
Can a diabetes medicine prevent dementia?
No diabetes medicine has been established by this evidence as a dementia-prevention treatment. Some observational studies have linked particular medicines with lower dementia incidence, but such studies cannot reliably separate a drug's effect from differences among the people taking it. Randomized trials provide a stronger test because treatment groups are assigned rather than simply observed. A 2024 review found no meaningful differences in dementia risk between diabetes drug classes and placebo in randomized trials, despite more favorable associations in observational research, according to Alzheimer's Research & Therapy.
The evidence therefore does not support prescribing metformin, GLP-1 drugs, SGLT2 inhibitors, or another diabetes drug specifically to prevent dementia. Medication decisions still need to reflect diabetes management, possible adverse effects, hypoglycaemia risk, and the individual's broader health needs. People should not stop, switch, or add medication based only on a dementia association. A clinician can review whether the current plan controls high glucose without creating avoidable lows.
What can a person do now?
The practical goal is risk reduction, not a guarantee. The CDC identifies uncontrolled diabetes, physical inactivity, high blood pressure, and tobacco use among dementia risks. Useful priorities include: Anyone experiencing repeated hypoglycaemia should discuss glucose targets and treatment with a clinician instead of changing doses independently.
- Follow the agreed diabetes plan and review HbA1c results with the treating clinician.
- Report repeated low glucose readings or symptomatic episodes rather than accepting them as the price of tighter control.
- Check whether blood pressure is being monitored and managed.
- Stay physically active at a level appropriate for current health and mobility.
- Seek support to stop smoking.
